Critical
Mashable
The U.S. International Trade Commission (ITC) has issued an order that could ban Apple Watch imports to the U.S., citing infringement on Masimo's patents for blood-oxygen tracking technology. This follows a January ruling in Masimo's favor and adds to Apple's ongoing IP disputes, including AliveCor's ECG-related claims. The Biden administration has 60 days to veto the order, though such actions are rare, leaving Apple's appeal process as its main option.
This ruling is part of a broader pattern of legal challenges targeting Apple's health-tech features. While a similar ITC ruling on AliveCor's patents remains unresolved, the Masimo case intensifies scrutiny on Apple's wearable innovations and its ability to navigate regulatory barriers.
Investment implication: A U.S. import ban on Apple Watch would disrupt a major revenue stream, as wearables contributed significantly to Apple's $41.2 billion in FY2025. For you, this highlights the potential for increased regulatory and legal risks to ripple across the health-tech market, affecting competitors, suppliers, and innovation strategies.